Michael J Rozema

This inventor holds 8 USPTO granted patents and 15 published patent applications, plus 8 CIPO patents and 3 EPO patents. Top assignees: Abbvie Inc., Abbott Laboratories Corporation, Reata Pharmaceuticals, Inc.. Active years: 2011-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael J Rozema. Retrieved from https://idiyas.com/inventor/michael-j-rozema

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 15)

% Patents Active = 50.0

CIPO Patents = 8 (Patent Applications = 6)

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 6.2

ph-index = 5

Forward Citations = 109(Granted Patents)

Company Filing History:

Abbott Laboratories Corporation

patents

1 out of 64

Reata Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2011-2022

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11512092 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2022-11-29),

2. 11198697 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2021-12-14),

3. 11186584 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2021-11-30),

4. 9464082 - Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators (2016-10-11),

5. 9260411 - Synthesis of (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile (2016-02-16),

6. 8691865 - Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers (2014-04-08),

7. 7960564 - Crystalline chemotherapeutic (2011-06-14),

8. 7947843 - Crystalline chemotherapeutic (2011-05-24),

Title: Unveiling the Innovative Mind of Inventor Michael J Rozema

Introduction:

Michael J Rozema, a prolific inventor hailing from Kenosha, WI (US), has made significant contributions to the field of pharmaceuticals with his groundbreaking patents and innovative processes.

Latest Patents:

Rozema's latest patents include processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof. These inventions are geared towards treating rheumatoid arthritis, spondyloarthritic conditions, and various types of axial spondyloarthritis, showcasing his commitment to advancing medical treatments.

Career Highlights:

With a total of 8 patents to his name, Rozema has established himself as a leading figure in the pharmaceutical industry. He has worked with renowned companies like AbbVie Inc. and Abbott Laboratories Corporation, demonstrating his versatility and expertise in the field.

Collaborations:

Throughout his career, Rozema has collaborated with esteemed professionals such as Thomas B Borchardt and Lakshmi Bhagavatula. These partnerships have not only enriched his inventions but have also led to the development of cutting-edge pharmaceutical products.

Conclusion:

Inventor Michael J Rozema's unwavering dedication to innovation and his commitment to improving healthcare through his patented processes exemplify the true spirit of creativity in the field of pharmaceuticals. His contributions continue to inspire and pave the way for future advancements in the industry.

Profile summary based on public USPTO records.